Research News
View articles by month and year
-
Tamoxifen Plus Removing Ovaries Improves Survival for Premenopausal Women
Removing the ovaries and taking tamoxifen after breast cancer surgery had benefits for premenopausal women shows a new study done in Vietnam and China.
-
Tamoxifen and Chemo Reduce Risk of New, Second Cancer
Tamoxifen and chemotherapy reduce the risk of developing a new, second breast cancer in the other breast.
-
Arimidex More Effective Than Tamoxifen for Postmenopausal Women
Another year of results from the ATAC trial continues to show that Arimidex has more benefits than tamoxifen for post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Postmenopausal Women Benefit from Longer Hormonal Therapy
Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.
-
Different Hormonal Therapies Cause Different Side Effects
Hormonal therapy medicines used to reduce the risk of recurrence have different side effects.
-
Women Stop Taking Hormonal Therapy Too Soon Because of Side Effects
Side effects cause many women to stop taking hormonal therapy medicine earlier than prescribed a new study reports.
-
Hormonal Therapy Medicines Have Improved Survival
Hormone-receptor-positive breast cancer survival rates have increased faster than survival rates for hormone-receptor-negative breast cancer.
-
Tamoxifen Plus Chemo Boosts Survival
Hormonal therapy and chemotherapy boosts survival for women with early breast cancer.
-
Aromatase Inhibitors Offer Better Survival Than Tamoxifen for Postmenopausal Women
Switching to an aromatase inhibitor after two to three years of tamoxifen offers improved survival compared to five years of tamoxifen for post-menopausal women with hormone-receptor-positive, early-stage breast cancer.
-
Too Many Women Stop Taking Tamoxifen Early
Many women stop taking adjuvant hormonal therapy medicine earlier than prescribed by their doctors.
